
Annual report 2024
added 12-27-2025
Midatech Pharma plc EBITDA 2011-2025 | MTP
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Midatech Pharma plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -7 M | -23 M | -11.3 M | -11.8 M | -13.3 M | -14.8 M | -12.2 M | -7.56 M | -4.25 M | - | - |
All numbers in GBP currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.25 M | -23 M | -11.7 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
Autolus Therapeutics plc
AUTL
|
-234 M | $ 1.87 | 11.68 % | $ 477 M | ||
|
Aclaris Therapeutics
ACRS
|
-141 M | $ 3.0 | -0.99 % | $ 232 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-17.3 M | $ 3.1 | -0.64 % | $ 7.46 B | ||
|
Alpine Immune Sciences
ALPN
|
-57.6 M | - | - | $ 2.17 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Aptorum Group Limited
APM
|
1.19 M | $ 1.1 | -3.51 % | $ 6 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
-11.4 M | - | 1.93 % | $ 17.4 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
AlloVir
ALVR
|
-200 M | - | 4.14 % | $ 49.1 M | ||
|
Ascendis Pharma A/S
ASND
|
-452 M | $ 211.15 | 1.04 % | $ 5 B | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
BioVie
BIVI
|
-17.8 M | $ 1.22 | 0.83 % | $ 1.8 M | ||
|
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | ||
|
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | ||
|
AVROBIO
AVRO
|
10.8 M | - | 1083.1 % | $ 745 M | ||
|
BioDelivery Sciences International
BDSI
|
37.3 M | - | -4.8 % | $ 255 M | ||
|
Athersys
ATHX
|
-85.6 M | - | 3.77 % | $ 22.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | ||
|
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-130 M | - | -15.15 % | $ 60.3 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-10.1 M | $ 0.17 | -18.84 % | $ 370 M | ||
|
Berkeley Lights
BLI
|
-89 M | - | -7.31 % | $ 87 M | ||
|
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | ||
|
BioNTech SE
BNTX
|
15.3 B | $ 95.17 | 0.69 % | $ 27.2 B | ||
|
Catalyst Biosciences
CBIO
|
-66.2 M | $ 12.12 | -1.86 % | $ 798 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
234 M | $ 26.86 | -0.96 % | $ 1.3 B | ||
|
BeiGene, Ltd.
BGNE
|
-396 M | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
-115 M | - | -10.95 % | $ 876 K | ||
|
Anika Therapeutics
ANIK
|
-81.2 M | $ 9.53 | -0.21 % | $ 140 M | ||
|
Certara
CERT
|
263 K | $ 8.85 | -0.45 % | $ 1.42 B | ||
|
bluebird bio
BLUE
|
-216 M | - | - | $ 546 M | ||
|
Cellectis S.A.
CLLS
|
-131 M | $ 4.95 | 4.2 % | $ 116 M | ||
|
Arena Pharmaceuticals
ARNA
|
-620 M | - | -6.81 % | $ 3.04 B | ||
|
Acer Therapeutics
ACER
|
-24.5 M | - | 2.71 % | $ 14 M | ||
|
Axon Enterprise
AXON
|
107 M | $ 583.1 | -0.13 % | $ 44.2 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-37.3 M | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
-2.45 M | $ 2.55 | 4.08 % | $ 16 M | ||
|
AstraZeneca PLC
AZN
|
1.06 B | $ 92.68 | -0.24 % | $ 96.9 B | ||
|
ChromaDex Corporation
CDXC
|
8.39 M | - | -0.88 % | $ 598 M | ||
|
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
-6.32 M | - | -5.38 % | $ 6.06 M | ||
|
Burford Capital Limited
BUR
|
242 M | $ 9.25 | 1.82 % | $ 1.49 B | ||
|
Celldex Therapeutics
CLDX
|
-192 M | $ 25.93 | -1.8 % | $ 1.67 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-679 M | $ 11.43 | 2.65 % | $ 739 M |